.jetcityimage/iStock Content using Getty Images Morgan Stanley has actually decided on Eli Lilly (NYSE: LLY) as its top biopharma selection for 2025 and rated another 9 names in the space as overweight. The financial investment banking company mentioned in a keep in mind that it remains to think “diabesity is readied to come to be.